May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Reduction of Macular Edema at One Hour Following Intravitreal Bevacizumab as Demonstrated by Serial Octs
Author Affiliations & Notes
  • D. E. Welch
    Ophthalmology, University of Florida, Gainesville, Florida
  • S. Adams
    Ophthalmology, University of Florida, Gainesville, Florida
  • M. Peden
    Ophthalmology, University of Florida, Gainesville, Florida
  • R. Ratnakaram
    Ophthalmology, University of Florida, Gainesville, Florida
  • S. Kaushal
    Ophthalmology, University of Florida, Gainesville, Florida
  • Footnotes
    Commercial Relationships  D.E. Welch, None; S. Adams, None; M. Peden, None; R. Ratnakaram, None; S. Kaushal, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 339. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. E. Welch, S. Adams, M. Peden, R. Ratnakaram, S. Kaushal; Reduction of Macular Edema at One Hour Following Intravitreal Bevacizumab as Demonstrated by Serial Octs. Invest. Ophthalmol. Vis. Sci. 2008;49(13):339. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Methods: : Subjects with either CSME or exudative ARMD receiving IV bevacizumab participated. ETDRS visual acuity and OCT measurement of macular thickness were obtained at baseline then at 1, 3, 6, 24 and 48 hours as well as at 1 week and 1 month post injection.

Results: : Six subjects with eight eyes have been enrolled to date. All were female with an average age of 58 years. Five were diagnosed with CSME and one with exudative ARMD. Planned comparisons with dependent sample t-tests revealed significant reduction in macular edema as measured by OCT at 1, 3, and 6 hours compared to baseline (mean reductions 13.9, t (7) = 2.35, p < 0.05; 22.63, t(7) = 3.13, p < 0.05; and 17.63, t (7) = 2.5, p < 0.05 respectively). When compared to baseline, there were no significant change in macular edema at 24 or 48 hours nor 1 week or 1 month. Additionally, there were no significant differences in visual acuity across times.

Keywords: imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • retinal neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×